Introduction
Gastrointestinal (GI) lymphomas are a relatively common type of extranodal lymphoma, accounting for up to 30-50% of extranodal lymphomas in some series[
1,
2]. However, the majority of population based studies have been performed on Asian or European cohorts[
2‐
9] with only one recent study from a Canadian-North American cohort[
10]. Though studies from the United States (US) have been performed, most are several decades old, and use nomenclature that predates the current World Health Organization (WHO) classification for lymphomas[
11,
12]. It is established that the prevalence of many gastrointestinal malignancies differs between continents. For example, the incidence of gastric adenocarcinoma is known to be substantially higher in Japan than in the US[
13]. Therefore, it stands to reason that the distribution of different lymphoma subtypes in the GI tract may differ between North America and other continents.
Specific genetic and epigenetic factors play a role in the pathogenesis of many lymphomas, including translocations (i.e.
API2-MALT1 CCND1-IGH)[
14], defects in tumor suppressor genes (i.e.
RB1 TP53 p15/
CDKN2B)[
15‐
19], and promoter hypermethylation of tumor suppressor genes (i.e.
p16/CDKN2A)[
20‐
22]. Promoter hypermethylation of
p16/CDKN2A occurs quite frequently in gastric lymphoid follicles with
Helicobacter pylori infection, gastric marginal zone lymphomas of mucosal associated lymphoid tissues (MALTs), and gastric diffuse large B cell lymphomas (DLBCLs), accounting for 10%, 41.7% and 72.7% of these cases, respectively in a Korean study[
22]. Some genetic perturbations have been shown to be characteristic of specific lymphomas of the GI tract. For example, the t(11;18)(q12;q21);
API2-MALT1 is relatively common in gastric MALTs, while it is less common in pulmonary MALTs, and is virtually never found in MALTs from other locations[
14]. Epidemiologic factors, such as
Helicobacter pylori infection in gastric MALTs[
14], are also known to be associated with some lymphoma subtypes.
Systemic lymphomas may secondarily involve the GI tract. However, the subtypes of lymphomas that affect the GI tract primarily versus secondarily have not been comprehensively detailed.
In the current study, we evaluated primary and secondary GI lymphomas diagnosed at Washington University Medical Center over the 10 year period from 2000–2009. We determined the frequency of involvement of different anatomic locations in the GI tract by different lymphoma subtypes. Gastric DLBCLs and MALTs were further studied to determine P16 and P53 expression, and the presence of IGH and API2-MALT1 rearrangements, to establish frequencies of these alterations in cases from a Central North American population. Our studies highlight there are distinct clinicopathologic features of primary and secondary GI lymphomas from a Central-Midwestern North American cohort.
Discussion
We undertook this 10 year retrospective study to evaluate the clinicopathologic and molecular features of GI lymphomas at a major US tertiary care medical center to determine the features of GI lymphomas in North America in comparison to other non-North American lymphoma cohorts. No previous extensive US study describing the primary and secondary GI lymphomas presenting in a Northern American population has been published that utilizes the current World Health Organization lymphoma classification. We show that there are distinct differences and similarities in our cases compared to other population based studies. Although many types of GI lymphomas were diagnosed, most of the cases presenting to our facility were referral cases initially diagnosed as lymphoma at an outside facility which were later referred to our facility for additional treatment. Thus, many of these patients had been treated with many different therapeutic regimens, so treatment regimens varied greatly among our cases and were too heterogenous to correlate treatments with clinical outcome in our analysis.
Several series from Europe, Canada-North America, and Asia have reported on primary GI lymphomas by lymphoma type and anatomic site[
2‐
5,
7,
9,
28‐
30]. Several trends emerge when reviewing the data collectively. First, primary gastric lymphomas tended to be more common than primary intestinal lymphomas in the European and Asian studies. Intestinal cases accounted for only 14%, 19%, 21%, 10%, 30%, 34%, 50% and 43% of cases in the Greek, Japanese, German, Austrian, Serbian, Turkish, Canadian-North American and Danish studies, respectively[
2‐
5,
7,
9,
28‐
30]. Gastric lymphomas accounted for >50% of total cases in most of these series. Our study stands in contrast to these, in that intestinal cases out-number gastric cases, accounting for 54% of total primary GI lymphomas. This difference noted in our study could be due to lower prevalence rates of
HP infection in the US resulting in fewer gastric MALTs diagnoses, earlier treatment for
HP infection resulting in fewer cases progressing to gastric MALTs, or that US patients with intestinal involvement have more severe symptoms such as intestinal obstruction and/or easier health care access resulting in more frequent visits to our tertiary care surgery facilities than patients with only solitary gastric involvement. The second trend to emerge is that high grade gastric lymphomas (i.e. gastric DLBCLs) tend to occur in approximately equal proportion to low grade gastric lymphomas (i.e. gastric MALTs). In this regard, our data are consistent with the European and Asian studies. Third, MALTs are much more common in the stomach than other sites, while DLBCLs tend to affect all segments of the GI tract. Our series also shows this trend to hold true.
Our study is also consistent with a recent study of primary GI FL from France by Damaj
et al., which showed that primary FL of the GI tract tends to be a disease of the small intestine[
31]. Similar findings were reported in a recent large US study which revealed small intestinal FLs made up 63% of cases while gastric FLs accounted for only 3% of primary gastrointestinal FLs[
32]. Similarly, 14 of the 25 (56%) of primary FLs in our series were found in the small intestine. No other low grade B lymphoma type in our series showed such a strong propensity for small intestinal involvement. In contrast to the study by Damaj
et al., which showed a female predominance, the small intestinal FLs in our series were equally distributed among men and women.
In examining the stage of presentation in our gastric MALTs and gastric DBLCLs, we also noted that gastric DLBCLs tended to have higher stage disease at presentation, while gastric MALTs often showed lower stage disease at presentation. Previous studies have shown that stage of lymphoma is an important prognostic predictor of clinical outcome, and that the lower grade gastric MALTs tend to have low stage while higher grade DLBCLs tend to have higher stage at presentation[
3,
4,
28,
33]. Thus, our study reveals that this association also occurs in the lymphomas from a Central North American population.
Environmental factors, especially
Helicobacter pylori (HP) infection, have been noted to play a prominent role in the development of gastric lymphomas[
34]. In 2 Italian studies,
HP has been reported to occur in 88% of low grade gastric MALTs identified by histologic examination, while it occurred at lower frequency (52-63%) in high grade gastric lymphomas[
28,
35]. Interestingly, both Italian studies revealed a statistically significant association between
HP infection and low grade gastric lymphoma (p < 0.0001)[
28,
35]. Similarly, a serologic study performed at a New York center showed
HP seroprevalence up to 67% in gastric MALTs, and increased seropositive rates were associated with increased age and country of birth outside the US or Canada (p = 0.0001)[
34]. Interestingly,
HP infection in our study was seen in only 24% of the gastric MALTs and 9% of the gastric DLBCLs by positive serology or histology, and we also noted higher frequency of
HP infection in the low grade gastric MALTs compared to high grade gastric DLBCLs. A 2008 Canadian-North American study also showed
HP infection in 20% of gastrointestinal non-Hodgkin lymphomas, of which 44% were in MALTs and 13% were in DLBCLs[
10]. The less frequent
HP infection rates in our cases could relate to our patient population having a higher percentage of patients born in the US or Canada, differences in the ethnicities of the Central-Midwestern compared to the New York population, or lower prevalence of
HP infection in the Midwest. Alternatively, the absence of serologic testing in all our cases, which may be more sensitive than histology in detecting
HP infections, could also contribute to a lower
HP prevalence rate in our gastric MALT patients.
Because of the high prevalence of genetic defects in
p16/CDNK2A in non-Hodgkin B cell lymphomas, we also evaluated P16 expression in our gastric MALTs and DLBCLs. Previous studies have shown that P16 is underexpressed more frequently in gastric MALT than in other lymphoma types[
20,
21]. This has been shown to primarily relate to
p16 promoter hypermethylation in non-transformed MALTs[
20,
36,
37]. As such,
p16 hypermethylation, and the resulting loss of P16 protein, is a high-frequency event in gastric MALTs occurring in up to 75% to 79% of cases in some studies[
20‐
22,
38,
39]. One Korean study by Min
et al. also showed increased frequency of
p16 hypermethylation in gastric DLBCLs (N = 11, 72.7%) compared to gastric MALTs (N = 24, 41.7%) and proposed that malignant transformation of gastric MALTs was attributed in part to
p16 hypermethylation[
22]. Our results confirm the prior findings that
p16 is frequently inactivated in gastric MALTs, since P16 expression was absent in 11 of 13 (85%) gastric MALTs, and expression was scored as 0 (i.e. less 5% of tumor cells positive) in these cases. In addition, P16 was expressed in only 3 of the 6 (50%) gastric DLBCLs. Most
p16 hypermethylation has been previously seen in
HP dependent cases. This fact may explain the weak P16 expression seen in one
HP + gastritis case we tested, but does not provide a mechanism for P16 loss in the our
HP- gastritis cases and
HP- gastric MALTs. Although the overall numbers of cases analyzed for P16 expression is low, our study showed no statistically significant difference was observed in P16 expression between gastric DLBCL and gastric MALT (p = 0.1078). Our result differs from the Korean study by Min
et al. that showed hypermethylation of
p16 (which can consequently downregulate P16 expression) to be more frequently associated with gastric DLBCLs compared to low grade gastric MALTs[
22]. Since the number cases in our study is only half as many as studied by Min
et al., other studies would be needed to determine if this association between
p16 hypermethylation (P16 expression loss) in high grade gastric DLBCLs holds true in other populations.
P53 over-expression has been shown to correlate with mutations in
TP53[
40]. This may relate to decreased rate of degradation of the mutant protein, leading to elevated cytoplasmic accumulation. P53 immunohistochemistry may be useful in evaluating primary GI lymphomas, because P53 accumulation has been shown to be more common in high grade lymphomas than low grade lymphomas[
41]. Moller
et al. showed that P53 protein overexpression, defined as ≥ 20% of tumor cells positive for P53, was 80-90% sensitive and 100% specific in predicting
TP53 mutations in DLBCLs[
42]. Moller
et al. also reported that p53 overexpression was an independent predictor of poor outcome in both T and B non-Hodgkin lymphomas (n = 199), and that P53 predicted poorer overall survival in indolent and aggressive non-Hodgkin lymphomas in addition to being associated with treatment failure and relapse-free survival. Using the same scoring criteria, high grade gastric DLBCLs were more significantly associated with P53 overexpression than low grade gastric MALTs in our series (p = 0.008). Thus our data corroborates the prior studies which have suggested mutations in
TP53 may relate to progression from low grade to high grade lymphoma, as well as increased risk of relapse[
19,
42].
Increased Ki-67 index has also been shown to correlate with increased grade of lymphoma[
41]. Our results were consistent with these previous observations, since all of our tested gastric DLBCLs had high Ki-67 index ≥80%, while the majority (85%) of the gastric MALTs had Ki-67 ≤20%. Statistical analysis on our lymphomas also showed higher Ki-67 levels were significantly associated with high grade lymphoma, specifically gastric DLBCL (p = 0.00042). Of note, the two MALTs with the highest Ki-67 index (50%) both showed strong P53 expression and an increased admixture of large B cells. This suggests they are not typical low grade MALTs, and likely are intermediate or transitional cases between a low grade and a high grade gastric B cell lymphoma. Alternatively, since these two gastric MALTs were diagnosed from small endoscopic biopsies, undersampling of a DLBCL on a small biopsy could also explain the P53 overexpression in these two outlier cases. Identification of a high proliferative index (Ki-67 >80%) on small gastric biopsies is also a helpful feature in diagnosing DLBCL, since all low grade gastric MALTs lacking evidence of large cell transformation (or admixed large cells) tend to show lower Ki-67 levels (≤20%). Assessment of the proliferative index may be a useful feature to study in small gastric biopsies with significant crushed features where morphologic evaluation is limited, and optimal grading and subtyping of the B cell lymphomas can be challenging due to the suboptimal quality of the biopsy.
The
API2-MALT1 translocation has been shown to be relatively frequent in gastric MALTs, and has been shown to predict both lack of resolution with
H. pylori eradication[
43] and resistance to further genetic damage[
44,
45]. Perhaps unsurprisingly, this translocation has been reported to be a rare event in gastric DLBCLs[
20,
45‐
47], indicating a gastric MALT with this translocation rarely progress to gastric DLBCL. Our series confirm these previous findings, as none of our gastric DLBCLs showed the
API2-MALT1 translocation, and none of the gastric MALTs with this translocation had concomitant
HP infection. In addition, this translocation was quite frequent (38%) in the gastric MALTs in our series, similar to the 17%-40% reported in other studies[
17,
18,
30,
48,
49].
Although
IGH translocations such as t(1;14)(p22;q32);
BCL10-IGH are reported in 3% of gastric MALTs and 5-10% of intestinal MALTs[
17,
18], we did not detect frequent
IGH translocations in this series, as our tested gastric MALTs were all negative. Only one duodenal MALT tested showed the
IGH translocation. Unfortunately, due to the absence of karyotype analysis, we could not further determine the partner gene for this case. Nevertheless, our data corroborates the prior data that an
IGH translocation (such as the
IGH-MALT1 IGH-BCL10 IGH-FOXP1), which is not the same as a clonal
IGH gene rearrangement detected by polymerase chain reaction analysis, is an infrequent genetic alteration in the pathogenesis of gastric MALTs.
In summary, our study highlights the differences in distribution and subtype of GI lymphomas at a large North American medical center. Secondary GI lymphomas were less frequent than primary GI lymphomas, and there were clear differences in frequency and subtype between primary and secondary cases. We confirm that certain genetic alterations occur frequently in GI lymphomas, such as loss of P16 protein expression and API2-MALT1 translocations in gastric MALTs, and P53 overexpression in gastric DLBCLs. However, we also found differences in the subtype, molecular, and clinical features in our Central-Midwestern North American patient population compared to other non-North American series.
Authors’ contributions
JW helped design the study, performed the epidemiological and immunohistochemical data analysis, and drafted the manuscript. JL performed statistical data analysis. DR and JB performed the cytogenetic data analysis. JLF helped design the project, contributed cases to the study, and helped write the manuscript. FK and AH contributed cases to the study, and helped write the manuscript. TN designed the study, coordinated the research efforts, carried out the histologic, immunohistochemical, and epidemiologic data review, and drafted the manuscript. All authors read and approved the final manuscript.